• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BDX

    Becton Dickinson and Company

    Subscribe to $BDX
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

    IPO Year:

    Exchange: NYSE

    Website: bd.com

    Peers

    $ABT
    $BAX
    $BSX
    $CAH
    $EW
    $MCK
    $MDT
    $SYK
    $TFX
    $TMO

    Recent Analyst Ratings for Becton Dickinson and Company

    DatePrice TargetRatingAnalyst
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    10/1/2024$255.00 → $275.00Neutral → Buy
    Citigroup
    5/30/2024$274.00Buy
    Goldman
    7/24/2023$305.00Mkt Perform → Outperform
    Raymond James
    See more ratings